DAY 1/THURSDAY, APRIL 11, 2024

	GENERAL SESSION
6:30 - 7:45 AM	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS | BALLROOM DE
7:45 - 8:00 AM	Welcome & Announcements SESSION A | CLASSIFICATION/EPIDEMIOLOGY/PROGNOSTIC FACTORS Primary Chair: Joan Guitart, MD Co-Chairs: Jose Antonio Sanches Junior, MD, PhD; Laura Pincus, MD; Elise A. Olsen, MD
8:00 - 8:20 AM	Overview & Updates in the Classification of Cutaneous Lymphomas Joan Guitart, MD
	A-01 The Modified TNMB Staging Criteria Fail to Identify Sézary Syndrome Patients with Low Blood Burden | Lauren Chrisman, BA A-02 Clinical Consequences of Reclassifying of Low-grade Malignant Cutaneous Lymphomas as Cutaneous Lymphoproliferative Disorders | Rein Willemze, MD A-03 Cutaneous Intravascular Lymphoproliferations: A Proposal for a Diagnostic Algorithm | Brandy Phan, BSA A-04 Racial Differences in the Skin Microbiome of Cutaneous T-Cell Lymphoma Patients | Yanzhen (Janet) Pang, BS A-05 The Impact of Lymph Node Clonality Status in the Prognosis of Mycosis Fungoides and Sézary Syndrome | Denis Miyashiro, MD, PhD A-06 The Role of Bone Marrow Biopsies in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma | Sima Rozati, MD, PhD A-07 Chronic Inflammatory Comorbidities in Primary Cutaneous Marginal Zone Lymphoma: Identifying the Underlying Cause | William Nguyen, BS A-08 Overlapping Diagnostic Criteria in Lymphomatoid Papulosis – A Prospective Multicenter Study On 141 Biopsy Specimens | Christina Mitteldorf, MD A-09 Prognostic Factors for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Multicenter Retrospective Study From Japan | Tomomitsu Miyagaki, MD, PhD A-10 Pediatric Cutaneous Lymphomas Including Rare Subtypes: A 40-Year Experience at a Tertiary Referral Center | Silvia Alberti-Violetti, MD, PhD A-11 Long Term Outcomes of Juvenile-onset Mycosis Fungoides | Rishabh Lohray, BS A-12 Clinical Characteristics and Outcome of Hypopigmented Mycosis Fungoides: A Retrospective Multicenter Study | Jongbin Park, MD, PhD
10:20 - 10:40 AM	REFRESHMENT BREAK/EXHIBITS/POSTERS
	Primary Chair: Emilio Berti, MD Co-Chairs: Christina Mitteldorf, MD; Kerri E. Rieger, MD, PhD
10:40 - 11:40 AM	A-13 Curing Advanced-Stage Mycosis Fungoides/ Sézary Syndrome | Seda Purnak, MD A-14 Patterns of Care in Cutaneous T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of  Outcomes (LEO) Prospective Cohort Study | Pamela Blair Allen, MD, MSc A-15 Primary Cutaneous Lymphomas/Lymphoproliferative Disorders with T-Follicular Helper Phenotype: A Tertiary Cancer Center Experience | Ziba Rahbar, MD, MPH A-16 T-Follicular Helper Immunophenotype in Mycosis Fungoides and Sézary Syndrome: A Clinico-Pathological Analysis of 33 Cases | Emilio Berti, MD A-17 Reactive T- and B-Cell Rich Lymphoid Proliferations – Spectrum and Subtypes | Werner Kempf, MD
11:40 AM - 12:10 PM	Primary Chair: Emmilia Hodak, MD Co-Chairs: Alejandro A. Gru, MD; Youn H. Kim, MD; Larisa J. Geskin, MD; Werner Kempf, MD Standardization of Clinical and Pathologic Reports of Mycosis Fungoides/Sézary Syndrome Emmilia Hodak, MD (Clinical) and Alejandro A. Gru, MD (Pathology)
12:10 - 12:45 PM	Zackheim Lecture Building Human Peripheral T-Cell Lymphoma Models for Biological and Therapeutic Investigations Wing C. (John) Chan, MD
12:45 - 1:45 PM	LUNCH/EXHIBITS/POSTERS
1:45 - 2:45 PM	POSTER/EXHIBIT RECEPTION
	SESSION C | BIOLOGIC INSIGHTS Primary Chair: Jaehyuk Choi, MD, PhD Co-Chairs: Sean Whittaker, MD; Michael Girardi, MD; Cornelis P. Tensen, PhD; Ivan V. Litvinov, MD, PhD
2:45 - 3:05 PM	Genomic Characterization of Cutaneous Lymphomas | Jaehyuk Choi, MD, PhD
3:05 - 5:05 PM	C-01 Molecular Profiling of Skin Lesions from a Patient with Angioimmunoblastic T-Cell Lymphoma in Comparison to Tumor-stage Mycosis Fungoides Reveals Disease-specific Markers | Emry Cohenour, MS C-02 Clinical-Pathologic Characterization of Gene-Fusion Positive Cutaneous T-Cell Lymphoma Cases | Liam Donnelly, MD C-03 Aberrant Serine Phosphorylation of STAT3 in Sézary Syndrome | Victoria Campbell, MSci, Mres C-04 Unraveling the Role of HDAC10 in the Molecular Background of Sézary Syndrome | Monika Pieniawska, MSc C-05 Tracing the Evolutionary Origins and Transcriptomic Variability in Sézary Syndrome and Mycosis Fungoides | Simon Cao, MPH C-06 Characterization of Genomic Changes in Large Cell Transformed Mycosis Fungoides and Sézary Syndrome | Jennifer Wang, MD C-07 Exploring the Role of Clonal T-LGL Proliferations in Cutaneous T-Cell Lymphoma | Yumeng (Julia) Zhang, MD C-08 MHC-I Upregulation Safeguards Neoplastic T-Cells in the Skin Against NK Cell-mediated Eradication in Mycosis Fungoides | Yun-Tsan Chang, PhD C-09 Next Generation Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma | Rebekah Wieland, MD, MS C-10 Bexarotene-induced Upregulation of Siglec-7 and Siglec-9 on Peripheral Blood T-Cells: A Potential Therapeutic Target | Miki Kume, MD, PhD
5:05 - 5:35 PM	DEBATE: The Origin of Mycosis Fungoides: Blood vs. Skin Moderator: Emmanuella Guenova, MD, PhD Robert Gniadecki, MD, PhD (Blood) and Michael Girardi, MD (Skin)
5:35 PM	CLOSING REMARKS/ADJOURN DAY ONE
6:00 - 8:00 PM	CONGRESS WELCOME RECEPTION | THE WESTIN PASADENA COURTYARD

DAY 2/FRIDAY, APRIL 12, 2024

	GENERAL SESSION
6:45 - 7:40 AM	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS | BALLROOM DE
7:40 - 7:50 AM	Welcome & Announcements AWARD SESSION: Emmilia Hodak, MD | ISCL Travel Scholarships & Susan Thornton | CLF Young Investigator Awards
	SESSION E | TUMOR MICROENVIRONMENT Primary Chair: Christiane Querfeld, MD, PhD Co-Chairs: Neda Nikbakht, MD, PhD; Gabor Dobos, MD, PhD; Florent Amatore, MD, PhD
7:50 - 8:10 AM	The Role of the Tumor Microenvironment | Christiane Querfeld, MD, PhD
8:10 - 10:10 AM	E-01 Single Cell Proteomic Analysis Defines a Deferential Exhausted Phenotype in Tumor Microenvironment with Mycosis Fungoides Progression | Evangelia Papadavid, MD, PhD E-02 Langerhans Cell Population Expands Early after Immune Checkpoint Inhibition in the Microenvironment of Mycosis Fungoides | Duncan Murray, MBChB, PhD E-03 Enhancing Anti-tumor Immunity by Targeting miR-146a and miR-21 in Mycosis Fungoides with Large-cell Transformation | Zhen Han, PhD E-04 The Microenvironment in Transformed Mycosis Fungoides: Increased NKG2A and its Role as a Potential Therapeutic Target | Pamela Blair Allen, MD, MSc E-05 Recombinant CD155 Promotes Tumor Cell Proliferation as well as IL-13 Expression in Cutaneous T-Cell Lymphoma | Ryoma Honda, MD E-06 OX-40 Promotes Tumor Progression in Cutaneous T-Cell Lymphoma by Regulating ERK Activation | Evangelia Papadavid, MD, PhD E-07 Total Skin Electron Beam Radiation Therapy is Associated with Enriched Cutaneous Microbial Diversity in Cutaneous T-Cell Lymphoma | Madeline J. Hooper, MD E-08 Cutaneous T-Cell Lymphoma Tumors Undergoing Radiation Demonstrate Shifts in Transcriptional Landscape from Malignant Inflammation to Wound Healing and Tissue Remodeling | Lauren Chrisman, BA E-09 Differences in the Spatially Resolved Transcriptome Profiles Leading to Progression in Mycosis Fungoides | Woo Jin Lee, MD, PhD
10:10 - 10:30 AM	REFRESHMENT BREAK/EXHIBITS/POSTERS
	Primary Chair: Patrick M. Brunner, MD, MSc | Co-Chair: Evangelia Papadavid, MD, PhD
10:30 - 11:05 AM	E-10 M2 Macrophages in the Cutaneous Microenvironment of Mycosis Fungoides and Sézary Syndrome and their Impact on Lymph Node Involvement | Daniel Montezzo, MD, PhD E-11 Tumor Promoting Activity of Toll-like Receptor 4 in the Cutaneous T-Cell Lymphoma Microenvironment | Neda Nikbakht, MD, PhD E-12 scRNA-Seq Reveals Differential Gene Expression of Cancer-associated Fibroblast Markers in Mycosis Fungoides by Stage and Race | Courtney M. Johnson, MD, PhD
11:05 - 11:35 AM	DEBATE: Allogeneic Transplant in Advanced Stage Disease: How Early Should We Do It in the Disease Course? Early vs. Late Moderator: Francine M. Foss, MD Swami P. Iyer, MBBS, MD (Early) and Wen-Kai Weng, MD, PhD (Late)
11:35 - 11:45 AM	AWARD SESSION: Emmilia Hodak, MD | ISCL 2024 Lifetime Achievement Awards
11:45 AM - 12:45 PM	LUNCH/EXHIBITS/POSTERS
12:45 - 1:20 PM	Plenary Lecture Advances & Limitations of CAR T-Cell Therapy | L. Elizabeth Budde, MD, PhD
	SESSION G | THERAPEUTICS/PRECLINICAL STUDIES Primary Chair: Michael Khodadoust, MD, PhD Co-Chairs: Ryan A. Wilcox, MD, PhD; Rudolf Stadler, MD, PhD; Jasmine Zain, MD
1:20 - 1:40 PM	The Treatment Landscape of Cutaneous T-Cell Lymphoma: Roadmap Towards Precision Medicine | Michael Khodadoust, MD, PhD
1:40 - 2:40 PM	G-01 Durvalumab (Anti-PD-L1) & Lenalidomide is Superior to Single-agent Durvalumab in Refractory/Advanced Cutaneous T-Cell Lymphoma | Christiane Querfeld, MD, PhD G-02 Mogamulizumab in Combination with Magrolimab (MoMa) in Previously Treated Mycosis Fungoides  and Sézary Syndrome | Michael Khodadoust, MD, PhD G-03 PTCL-002 Updates: Pembrolizumab in Combination with Epigenetic Therapy is Safe and Shows Activity in CTCL and PTCL | Nathan Roberts, MD G-04 Generation and Optimization of Off-the-Shelf Immunotherapeutics Targeting TCR-Vbeta2+ T-Cell Malignancy | Michael Girardi, MD G-05 Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Excellent Disease Control in Patients with Refractory/Relapsed Cutaneous Cytotoxic T-Cell Lymphoma | Wen-Kai Weng, MD, PhD
2:40 - 3:00 PM	REFRESHMENT BREAK/EXHIBITS/POSTERS
	Primary Chair: H. Miles Prince AM, MBBS (Hons), MD Co-Chairs: Pierluigi Porcu, MD; Richard Cowan, MD; Brad Haverkos, MD; Auris Huen, MD, PharmD
3:00 - 4:00 PM	G-06 Management of Relapsed Cutaneous T-Cell Lymphoma after Allogeneic Transplantation | Wen-Kai Weng, MD, PhD G-07 Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced CTCL: A Single-Centre Experience Including 63 Patients | Francesco Onida, MD G-08 Allogeneic Stem Cell Transplant for Treatment of Mycosis Fungoides and Sézary Syndrome: A Systematic Review and Meta-analysis | Francine M. Foss, MD G-09 Is Prolonged Treatment with Brentuximab an Alternative? Real-life Experience on Mycosis Fungoides/Sézary Syndrome Patients | Jade Cury-Martins, MD, PhD G-10 Methotrexate Single Agent and Combination Treatment in Mycosis Fungoides and Sézary Syndrome. A Multicenter, Retrospective Study | Silvia Alberti-Violetti, MD, PhD
4:00 - 5:00 PM	G-11 Safety and Tolerability of E7777 (Improved Purity Denileukin Diftitox) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302| H. Miles Prince AM, MBBS (Hons), MD G-12 Treatment of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-type (PCDLBCL-LT) in the Modern Era | Tarek Bandali, MD G-13 Mogamulizumab Combined with Extracorporeal Photopheresis (ECP) as a Novel Therapy in Erythrodermic Cutaneous T-Cell Lymphoma | Jan Nicolay, MD, MSc G-14 Preliminary Data of Efficacy and Tolerability of Chlormethine Gel with and without Combined Systemic Therapy – A Multicenter Retrospective Study of the German Lymphoma Group | Christina Mitteldorf, MD G-15 Efficacy and Safety of E7777 (Improved Purity Denileukin Diftitox) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 | Francine M. Foss, MD
5:00 PM	CLOSING REMARKS/ADJOURN DAY TWO
6:00 - 7:00 PM	SHUTTLE FROM HOST HOTEL (THE WESTIN PASADENA) TO CONGRESS GALA DINNER Shuttle sponsored by Kyowa Kirin
7:00 - 10:00 PM	CONGRESS GALA DINNER Not included in congress registration. Prepaid ticket is required.
10:00 - 10:30 PM	SHUTTLE FROM CONGRESS GALA DINNER TO HOST HOTEL Shuttle sponsored by Kyowa Kirin

DAY 3/SATURDAY, APRIL 13, 2024

	GENERAL SESSION
7:00 - 7:30 AM	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS | BALLROOM DE
7:30 - 8:00 AM	ISCL ASSEMBLY MEETING (NON-CME ACCREDITED)
8:00 - 8:05 AM	Welcome & Announcements SESSION I | CHALLENGING CASES OF CUTANEOUS LYMPHOMAS Primary Chair: Pietro Quaglino, MD Co-Chairs: Stefan K. Barta, MD, MS; Iris Amitay-Laish, MD; Paula Enz, MD
8:05 - 8:25 AM	Facts and Controversies in Cutaneous B-Cell Lymphomas | Pietro Quaglino, MD
8:25 - 10:25 AM	I-01 EBV Positive Primary Cutaneous Marginal Zone Lymphoma with Transformation to Plasmablastic Lymphoma | Jack Reid, MD I-02 Brentuximab Vedotin-associated Tumor Flare Response in a Patient with Mycosis Fungoides with Large Cell Transformation | Rishabh Lohray, BS I-03 Mogamulizumab-induced Bone Granuloma: A Multicentre Nationwide Case Series | Florent Amatore, MD, PhD I-04 Pemphigus Foliaceous after Total Skin Electron Beam Radiation for Mycosis Fungoides | Leah Cohen, MD I-05 Advanced Mycosis Fungoides/Sézary Syndrome Masquerading Atopic Dermatitis in the Era of Advanced Therapeutics – Clues and Pitfalls | Iris Amitay-Laish, MD I-06 Molecular Genetic Demonstration of the Evolution of Transformed Mycosis Fungoides: A Clinicopathological and Molecular Case Study | Melissa Cheng, BS I-07 I ncreased Incidence of Second Primary Malignancies in Patients with Primary Cutaneous B-Cell Lymphomas: A SEER Population Study | Henry Yang, BS I-08 Bcl6 Expression in a T-Cell Infiltrate…Think Follicular Helper T-Cell Lymphoma | Jacqueline M. Junkins-Hopkins, MD I-09 Co-expression of CD3 and CD20: A Clue to the Diagnosis of Intestinal Lymphoma Presenting in the Skin | Nina Martins, BA I-10 Molecularly-annotated Case of a CD30-Positive Gamma-delta T-Cell Features of Primary Cutaneous Anaplastic Large Cell Lymphoma: A Wolf in Sheep’s Clothing? | Robert E. LeBlanc, MD I-11 Hydroa Vacciniforme-like Lymphoproliferative Disorder in a Young Asian Female | Ziqi Liu, MD I-12 Atypical Presentation of Gamma/Delta (γ/δ) Mycosis Fungoides with an Unusual Phenotype and SOCS1 Mutation | Pia Rude Nielsen, MD, PhD
10:25 - 10:45 AM	REFRESHMENT BREAK/EXHIBITS/POSTERS
10:45 - 11:15 AM	DEBATE: Epidermotropic Cutaneous T-Cell Lymphoma with Gamma-delta Phenotype: Is it Mycosis Fungoides or Gamma-delta T-Cell Lymphoma? Moderator: Werner Kempf, MD Alejandro A. Gru, MD (Mycosis Fungoides) and Joan Guitart, MD (Gamma-delta T-Cell Lymphoma)
11:15 - 11:55 AM	Cutaneous T-Cell Lymphoma Jeopardy Moderator: Matt Lunning, DO H. Miles Prince AM, MBBS (Hons), MD and Evangelia Papadavid, MD, PhD Chalid Assaf, MD, PhD and Jasmine Zain, MD Emmanuella Guenova, MD, PhD and Steven M. Horwitz, MD
11:55 AM - 12:35 PM	Best of Congress Youn H. Kim, MD (Therapeutics) and Pablo L. Ortiz-Romero, MD, PhD (Non-Therapeutics)
12:35 PM	CLOSING REMARKS/ADJOURN CONGRESS AND LUNCH
1:30 PM	SHUTTLE FROM PASADENA CONVENTION CENTER TO THE HUNTINGTON LIBRARY Shuttle sponsored by CRISPR Therapeutics
2:00 - 5:00 PM	THE HUNTINGTON LIBRARY Not included in congress registration. Preregistration/ticket is required.
5:15 PM	SHUTTLE FROM THE HUNTINGTON LIBRARY TO HOST HOTEL Shuttle sponsored by CRISPR Therapeutics